A mutation in the FAAH gene that enhances endocannabinoid signaling has been difficult to decipher, as it exists only in humans. A new study reports a knock-in mouse expressing an identical mutation, bridging an important translational gap.
''As little as five years ago,'' William Devane recalled, ''most articles concerning the molecular pharmacology of cannabinoid drugs began with the standard refrain 'the cellular bases of cannabinoid actions are unknown''' [1] . The year was 1994, and Devane declared a ''New dawn of cannabinoid pharmacology'' [1] . Twenty years later, and many chemical footsteps ahead, cannabinoid research remains closer to bench than bedside. In the sociopolitical climate of 2015, translational research is held back by fierce debates over medicinal cannabis legalization. Clinical studies face two translational roadblocks: the first is to harness basic scientific knowledge into production of new drugs, devices and treatments; the second is to bring these promising products to market, and make sure they actually reach those who need them [2] . Translational research of the cannabinoid systems, it seems, has passed the second hurdle before overcoming the first.
Since California's Compassionate Use Act of 1996, over 23 U.S. states and the District of Columbia have legalized cannabis for medical use. Yet, the neural bases of cannabinoid actions in the human brain are largely unknown (Figure 1 ). Understanding the human cannabinoid system depends heavily on animal research. Animal models are the platform for fine-grained molecular and cellular analysis that is beyond the reach of human brain science. Still, many basic findings in animals never lead to clinical trials. A critical requirement for successful translation is that the phenomenon of interest would have similar phenotypic expression across species. Satisfying this criterion has been especially challenging in the case of the fatty acid amide hydrolase (FAAH) gene of the endocannabinoid system. A single-nucleotide polymorphism in this gene correlates with anxiety in humans [3] . But a major obstacle for animal models seeking to characterize this polymorphism is that the FAAH variant exists only in the human brain. A new study by Dincheva et al. [4] has found a way around it. The study reports the development of a knock-in mouse expressing an identical single-nucleotide mutation of the human FAAH gene.
In 1988, while in graduate school, William Devane proved the existence of the cannabinoid receptor in the rat brain [5] . By then, the active ingredient in marijuana that triggers this receptor, tetrahydrocannabinol (THC), had been long known -Rapahel Mechoulam successfully isolated THC from the cannabis plant in 1964 [6] .
The missing piece in the puzzle was the identity of the brain chemical, or endogenous ligand, that naturally binds the cannabinoid receptor. Devane joined Mechoulam's lab as a postdoc, to search for the internal equivalent of the exogenous THC. A few years later, Devane found the endogenous ligand [7] and named it 'anandamide', from the Sanskrit word ananda, meaning 'bliss'.
A blissful function of the endocannabinoid system is its ability to relieve pain and anxiety [8] . Perhaps for that reason alone, several states have already approved treating posttraumatic stress disorder (PTSD) with marijuana and synthetic cannabinoids, despite the lack of clinical trials substantiating the medicinal efficacy of cannabis in PTSD [9] . Studies in animals, though, do compellingly show that endocannabinoid manipulations influence threat learning [10, 11] . At the forefront of PTSD treatment is prolonged exposure therapy [12] . An animal model that captures this therapy's cognitive and behavioral core is extinction of threat learning [13] . To mimic a traumatic event in the laboratory, the animal undergoes threat conditioning by associating a neutral stimulus with a negative outcome; extinction training follows, where the animal repeatedly encounters the conditioned stimulus but the negative outcome is gone. The animal then exhibits less of the conditioned defensive responses in the presence of the no-longer threatening cue [14] , a process relying on neural circuits that often go awry in PTSD [15] .
Animal studies of threat learning have consistently shown a relationship between the cannabinoid system and the ability to extinguish fear, indicating that drugs that trigger cannabinoid receptors could potentially aid exposure therapy in PTSD [9] [10] [11] . But such global pharmacological intervention in cannabinoid receptor activation may provoke risky side effects and even opposite results [16] . A more nuanced approach would be to elevate endocannabinoid neurotransmitter availability in the synapse. The beauty of this approach is that it enhances anandamide levels only in the specific regions where it was released [17] . This is where FAAH comes into play.
FAAH is the catabolic enzyme that leads to the breakdown and degradation of anandamide, thereby regulating anandamide signaling in the brain [17] . About 38 percent of people of European descent are carriers of the FAAH gene variant (C385A; AC and AA genotypes) [18] . In the FAAH single-nucleotide polymorphism, a threonine (A) residue substitutes the evolutionarily conserved proline (C). The mutated FAAH protein suffers folding abnormalities that render it more vulnerable to proteolytic degradation, which in turn rescues anandamide from degradation [19] . If carriers of the A-allele gain enhanced endocannabinoid signaling, would they better cope with threat?
The road to elucidating the human endocannabinoid system passes through the mouse brain, and the knock-in mice that Dincheva et al. [4] engineered to carry the FAAH gene variant paved the way. Human carriers of the A-allele typically exhibit lower levels of the FAAH protein in their lymphocytes, but whether parallel alterations of the endocannabinoid system in the human brain accompany these changes in peripheral tissues has been unclear. Dincheva et al. [4] found that their knock-in mice expressing the A-allele had lower FAAH protein levels in the forebrain, together with increases in anandamide levels. These findings validate the FAAH C385A knock-in mice as a mouse model mirroring the phenotypic expression of the FAAH polymorphism in humans.
Dincheva et al. [4] then used this model to explore higher-level neural and behavioral processes. They found that both human and mice carriers of the A-allele better extinguished conditioned threat responses, consistent with previous studies linking the FAAH polymorphism with individual differences in reactivity to threat [3] . These findings imply that the FAAH gene perhaps alters the neurocircuitry of extinction learning. The ability to modulate threat learning relies on the integrity of the ventromedial prefrontal cortex and its modulatory connections with the amygdala [20] . Using neuroimaging, Dincheva et al. [4] indeed found greater resting-state functional connectivity between the amygdala and ventromedial prefrontal cortex in human participants. To delineate the neuroanatomical connections that might allow the two regions to co-activate, Dincheva et al. [4] used their mouse model to test genotypic differences in any of the neural tracts connecting the two regions. They injected anterograde and retrograde tracers into the medial prefrontal cortex of the knock-in mice and revealed an increase in the projections descending from the infralimbic region of the medial prefrontal cortex to the amygdala, which is the specific pathway that is critical for extinction learning and memory [20] .
This unique biochemical, neural, and behavioral signature of A-allele carriers might explain why some PTSD patients respond better to exposure therapy and to certain cannabinoid drugs. Such findings could steer future therapies involving the endocannabinoid system toward a more precise and personally tailored care. While scientists are laboring to keep up with legislators, medicinal cannabis spreads faster than the narrowing translational gap. But the stride of discoveries in endocannabinoid research have opened the door, in the words of William Devane, to a new dawn of cannabinoid-based therapy. 
Dispatches
Extensive sequencing of transcriptomes reveals the evolutionary relationships among the major flatworm lineages, suggesting new roots and conflicting routes to parasitism.
Linnaeus had little time for worms, pooling them with other invertebrates into the group 'Vermes'. Beguilingly simple, vermiform (worm-like) organisms include some of the most important species ecologically, evolutionarily, economically and biomedically. On closer examination, few vermiform creatures are truly simple, and many have provided a rich source of evolutionary novelties sparking major radiations. The flatworms are particularly notable (Figure 1 ). Dorsoventrally flattened with no body cavity other than a gut (acoelomate), flatworms have long been considered simple in body plan and suitable as a starting point in devising other more complex animal forms. We know that other 'flat worms' such as acoels [1] and xenoturbellids [2] have pivotal, but still controversial, roles in disentangling the tree of life depending on their true position. Originally placed deep at, or towards, the base of all bilaterally symmetrical animals, these flattened worms are now considered more closely related to echinoderms and vertebrates. True flatworms (phylum Platyhelminthes) are nested securely, but not clearly amongst the Lophotrochozoa [3] , a major grouping amongst the invertebrates. The disparate positions of flatworms, acoels and xenoturbellids on the metazoan tree throws up some weird and wonderful conundra, such as the origins and evolution of the anus, the blastopore and the mouth [4] . With 30,000 described species, and many more likely to be discovered across their global range, the Platyhelminthes reflect a rich source of evolutionary innovation [5] . Including a plethora of active aquatic microscopic forms living on and between sand grains, planarians with remarkable regenerative properties, multicolored worms found on coral reefs, the free-living forms are everywhere but rarely obvious. Flatworms are most numerous as parasites with simple or complex life cycles, attaching themselves on and in other animals. From blooddwelling flukes to gut-inhabiting tapeworms, their success can be measured in species number, diversity, biomass or sheer wonderment as to how they complete their life cycles. Host-to-host transmission, behavioural manipulation, fecundity and specificity for host or even site of infection can each be astounding. Flatworm parasitism is also associated with diseases including debilitating and lethal helminthiases in humans (schistosomiasis, echinococcosis, cysticercosis) and
